drugset / Trial / NCT02736318

OD-PHOENIX in Talus Osteochondral Lesion

NCT02736318 ↗

Phase 1/2 Terminated 12 enrolled TBF Genie Tissulaire
NaSingle-groupOpen-labelTreatment

Summary

Treatment of osteochondral lesion of Talus with a devitalized viro-inativated sterile osteochondral graft. To avoid having to harvest autograft material from the knee, a processed allogeneic osteochondral can be used instead autograft. The surgical technique is to implant in the osteochondral defect one to three products in the defect.

Timeline

Start
2017-01-27
Primary completion
2021-09-07
Completion
2021-09-07

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual rate”

Drugs

EvaluationDrugModalityDoseRoute
Subject OD-PHOENIX Other / unclassified — —

Indications

No indication recorded.